PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-14-1246PMID 25398439
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation

  2014cited by this paper
• Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

  2014influential reference
• Log-Rank Test

  2014cited by this paper
• Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma

  2014cited by this paper
• Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

  2014cited by this paper
• PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma

  2014cited by this paper
• Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls

  2013cited by this paper
• Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

  2013cited by this paper
• Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

  2013cited by this paper
• Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells

  2013cited by this paper
• Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma

  2013cited by this paper
• The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

  2013cited by this paper
• Targeting oxidative stress in embryonal rhabdomyosarcoma.

  2013cited by this paper
• Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes

  2013cited by this paper
• PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma

  2013cited by this paper
• P-cadherin is a direct PAX3–FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

  2013influential reference
• Rapid determination of multiple linear kinase substrate motifs by mass spectrometry.

  2012cited by this paper
• PAX3‐FOXO1 and FGFR4 in alveolar rhabdomyosarcoma

  2012influential reference
• PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

  2012cited by this paper
• Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

  2011cited by this paper
• Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS)

  2010cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Cancer esearch cular and Cellular Pathobiology ome-Wide Identification of PAX 3-FKHR Binding Sites in bdomyosarcoma Reveals Candidate Target Genes R ortant for Development and Cancer

  2010influential reference
• BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

  2009influential reference
• Immunohistochemical detection of EGFR, fibrillin‐2, P‐cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnostics

  2009cited by this paper
• Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

  2009cited by this paper
• Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.

  2008cited by this paper
• PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

  2008cited by this paper
• Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.

  2008cited by this paper
• BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

  2007cited by this paper
• The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis.

  2007cited by this paper
• Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR

  2007cited by this paper
• Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas

  2007cited by this paper
• The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

  2007cited by this paper
• Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration.

  2006cited by this paper
• Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3‐FKHR positive and negative tumors

  2006cited by this paper
• Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.

  2006cited by this paper
• Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry.

  2006cited by this paper
• Targeting polo-like kinase 1 for cancer therapy

  2006cited by this paper
• Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1

  2004cited by this paper
• Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

  2003cited by this paper
• PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

  2002cited by this paper
• Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion

  2002cited by this paper
• Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.

  2000cited by this paper
• Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression

  2000cited by this paper
• PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt

  1999cited by this paper
• Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.

  1998cited by this paper
• Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.

  1997cited by this paper
• Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.

  1996cited by this paper
• Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins.

  1996cited by this paper
• Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors.

  1994cited by this paper

• Proteomic Profiling Reveals Candidate Proteins and Pathways Associated with Chemo-Radio-Sensitivity and Relapse in Rhabdomyosarcoma.

  2026cites this paper
• PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities

  2025cites this paper
• Oncogenic Fusions with Aberrant Transcriptional Regulation.

  2025cites this paper
• Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls

  2025cites this paper
• Rhabdomyosarcoma: development of molecular therapeutics under the microscope

  2025cites this paper
• FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking

  2025cites this paper
• Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma

  2025cites this paper
• Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2.

  2024cites this paper
• Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders

  2024cites this paper
• Caspase-Activated DNase localizes to cancer causing translocation breakpoints during cell differentiation

  2024cites this paper
• FusOn-pLM: A Fusion Oncoprotein-Specific Language Model via Focused Probabilistic Masking

  2024cites this paper
• The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors

  2023cites this paper
• TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Regulatory RNAs in the Molecular Pathology of Neoplasia

  2022cites this paper
• Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.

  2022cites this paper
• Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.

  2021cites this paper
• Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs

  2021cites this paper
• BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma

  2021cites this paper
• Molecular mechanisms underpinning sarcomas and implications for current and future therapy

  2021cites this paper
• Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications

  2020cites this paper
• Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies

  2019influential citation
• A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas

  2019cites this paper
• Current and Future Treatment Strategies for Rhabdomyosarcoma

  2019cites this paper
• Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors

  2019cites this paper
• Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with Navitoclax to induce Rhabdomyosarcoma cell death.

  2019cites this paper
• Rhabdomyosarcoma

  2019cites this paper
• University of Birmingham A perspective on polo-like kinase-1 inhibition for the treatment of rhabdomyosarcoma

  2019cites this paper
• Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting PLK1 expression.

  2018cites this paper
• Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma

  2018influential citation
• Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma

  2018cites this paper
• Fusion gene addiction: can tumours be forced to give up the habit?

  2017cites this paper
• PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.

  2017cites this paper
• PAX3-FOXO1: Zooming in on an "undruggable" target.

  2017cites this paper
• PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

  2017cites this paper
• Title : PAX 3-FOXO 1 establishes myogenic super enhancers and confers BET bromodomain vulnerability

  2017cites this paper
• Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options

  2016cites this paper
• Uncovering metabolism in rhabdomyosarcoma

  2016cites this paper
• PLK1, A Potential Target for Cancer Therapy

  2016cites this paper
• Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

  2016cites this paper
• RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.

  2016cites this paper
• Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.

  2016cites this paper
• Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems

  2015cites this paper
• The Role of Secreted Frizzled Related Protein 3 (SFRP3) and the Wnt Signaling Pathway in PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma

  2015cites this paper
• Less Can Be More for Gene Dose and Drug Sensitivity

  2015cites this paper
• Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs

  2015cites this paper
• Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation

  2015cites this paper
• Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells

  2015cites this paper